JP7706166B2 - タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤 - Google Patents

タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤 Download PDF

Info

Publication number
JP7706166B2
JP7706166B2 JP2022517372A JP2022517372A JP7706166B2 JP 7706166 B2 JP7706166 B2 JP 7706166B2 JP 2022517372 A JP2022517372 A JP 2022517372A JP 2022517372 A JP2022517372 A JP 2022517372A JP 7706166 B2 JP7706166 B2 JP 7706166B2
Authority
JP
Japan
Prior art keywords
degrees
formula
crystal
powder
angstroms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022517372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548689A (ja
JP2022548689A5 (enExample
Inventor
ツァオ，ガンフォン
リー，チュン
ジャン，フアピン
ユー，ホンウー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prelude Therapeutics Inc
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of JP2022548689A publication Critical patent/JP2022548689A/ja
Publication of JP2022548689A5 publication Critical patent/JP2022548689A5/ja
Application granted granted Critical
Publication of JP7706166B2 publication Critical patent/JP7706166B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
JP2022517372A 2019-09-18 2020-09-18 タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤 Active JP7706166B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902322P 2019-09-18 2019-09-18
US62/902,322 2019-09-18
PCT/US2020/051563 WO2021055797A1 (en) 2019-09-18 2020-09-18 Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Publications (3)

Publication Number Publication Date
JP2022548689A JP2022548689A (ja) 2022-11-21
JP2022548689A5 JP2022548689A5 (enExample) 2023-09-25
JP7706166B2 true JP7706166B2 (ja) 2025-07-11

Family

ID=72717922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517372A Active JP7706166B2 (ja) 2019-09-18 2020-09-18 タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤

Country Status (12)

Country Link
US (2) US12414953B2 (enExample)
EP (1) EP4031555A1 (enExample)
JP (1) JP7706166B2 (enExample)
KR (1) KR20220065811A (enExample)
CN (1) CN114829370B (enExample)
AU (1) AU2020349553A1 (enExample)
BR (1) BR112022004630A2 (enExample)
CA (1) CA3154566A1 (enExample)
IL (1) IL291417B2 (enExample)
MX (1) MX2022003340A (enExample)
WO (1) WO2021055797A1 (enExample)
ZA (1) ZA202203680B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116211869B (zh) * 2022-12-07 2023-08-01 浙江省肿瘤医院 含dna损伤修复抑制剂的药物混合物及混合方法、用途
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2017032840A1 (en) 2015-08-26 2017-03-02 Janssen Pharmaceutica Nv Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
JP2017525667A (ja) 2015-05-04 2017-09-07 イーライ リリー アンド カンパニー ５′−置換ヌクレオシド化合物
WO2017153186A1 (en) 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
JP2018510850A (ja) 2015-02-24 2018-04-19 ファイザー・インク 抗がん剤として有用な置換ヌクレオシド誘導体
WO2019032859A1 (en) 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
WO2019084470A1 (en) 2017-10-26 2019-05-02 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
JP7328241B2 (ja) 2018-03-14 2023-08-16 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2016022605A1 (en) * 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
MA41827A (fr) * 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
CN108430987B (zh) * 2016-06-02 2021-06-18 上海海雁医药科技有限公司 Pi3k抑制剂及其药学上可接受的盐和多晶型物及其应用
WO2017218802A1 (en) * 2016-06-15 2017-12-21 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
TN2019000087A1 (en) * 2016-10-03 2020-07-15 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
KR101785870B1 (ko) 2016-11-03 2017-10-13 한규락 오르골 장치

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2018510850A (ja) 2015-02-24 2018-04-19 ファイザー・インク 抗がん剤として有用な置換ヌクレオシド誘導体
JP2017525667A (ja) 2015-05-04 2017-09-07 イーライ リリー アンド カンパニー ５′−置換ヌクレオシド化合物
WO2017032840A1 (en) 2015-08-26 2017-03-02 Janssen Pharmaceutica Nv Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
WO2017153186A1 (en) 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
WO2019032859A1 (en) 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
WO2019084470A1 (en) 2017-10-26 2019-05-02 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
JP7328241B2 (ja) 2018-03-14 2023-08-16 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIN, Hong et al.，"Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors"，ACS Medicinal Chemistry Letters，2019年05月22日，Vol. 10，No. 7，p. 1033-1038，DOI: http://dx.doi.org/10.1021/acsmedchemlett.9b00074

Also Published As

Publication number Publication date
IL291417B2 (en) 2025-12-01
US12414953B2 (en) 2025-09-16
CN114829370B (zh) 2025-10-28
WO2021055797A9 (en) 2021-04-22
AU2020349553A1 (en) 2022-04-07
BR112022004630A2 (pt) 2022-05-31
IL291417B1 (en) 2025-08-01
WO2021055797A1 (en) 2021-03-25
JP2022548689A (ja) 2022-11-21
US20230029094A1 (en) 2023-01-26
CA3154566A1 (en) 2021-03-25
MX2022003340A (es) 2022-06-14
IL291417A (en) 2022-05-01
CN114829370A (zh) 2022-07-29
KR20220065811A (ko) 2022-05-20
EP4031555A1 (en) 2022-07-27
US20250367205A1 (en) 2025-12-04
ZA202203680B (en) 2025-12-17

Similar Documents

Publication Publication Date Title
EP3665179B1 (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
JP7328218B2 (ja) タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
US20250367205A1 (en) Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
US20220160713A1 (en) Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
JP2025510738A (ja) 多型化合物及びその使用
EA044352B1 (ru) Селективные ингибиторы протеинаргининметил трансферазы 5 (prmt5)
WO2025194405A1 (en) Polymorphic smarca inhibitors and uses thereof
JP2023526235A (ja) 骨髄性細胞白血病－１（ｍｃｌ－１）タンパク質の阻害剤としてのスピロ－スルホンアミド誘導体
EA043295B1 (ru) Селективный ингибитор протеин-аргинин-метилтрансферазы 5 (prmt5)
HK40067540A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EP4729519A1 (en) Crystal form of enpp1 inhibitor
HK40031042A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
HK40031042B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250624

R150 Certificate of patent or registration of utility model

Ref document number: 7706166

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150